Abstract:10612 Background: Population-based screening for hereditary cancer syndromes and referral of those who screen positive for genetic testing is a cost effective, evidence-based national health priority. However, under-recognition of hereditary cancer syndromes remains a critical concern, with fewer than 20% of individuals with Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome identified. Here, we evaluate the Ambry Genetics Comprehensive, Assessment, Risk, and Education (CARE) Program, a risk-stratification tool to assess eligibility for National Comprehensive Cancer Network (NCCN) genetic testing criteria and lifetime risk for breast cancer based on the Tyrer-Cuzick (version 8.0) risk algorithm. Methods: Between November 2022 and February 2023, new patients in a gynecologic oncology clinic were prompted by text message to complete CARE prior to their appointment. Those using CARE then completed a System Usability Scale (SUS), a validated 10-item questionnaire for the assessment of perceived usability. Results: Sixty patients presented for a new patient gynecologic oncology appointment and were prompted to complete CARE. The median patient age was 55 years (interquartile range, 40-68). The patients self-identified as Non-Hispanic White (44, 73%), Non-Hispanic Black (5, 8%), Asian (5, 8%), Hispanic (3, 5%), other (2, 3%), and unknown (1, 2%). All identified as female. Forty-three patients (72%) completed CARE. Among CARE users, 11 (26%) were identified as meeting criteria for genetic testing; of these, 9 (82%) proceeded with point-of-care same day genetic testing. Nine (21%) patients were eligible for enhanced breast cancer screening based on an estimated lifetime breast cancer risk of 20% or greater; of these, 100% were referred for high-risk breast screening. There were no patient demographics associated with completion of CARE. Forty-one patients (72%) completed the SUS survey; the median SUS score was 80 (interquartile range, 60-92.5), which corresponded to 85-89th percentile and a letter grade of A-. Conclusions: Implementation of a digital tool for cancer genetic risk assessment identified a quarter of patients to be eligible for genetic testing, among whom 82% completed same-day genetic testing. Additionally, the tool was reviewed favorably by patient users. Large randomized controlled trials of health information technology tools are needed to move closer to the goal of population-based hereditary cancer risk assessment.

What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries

BREAst screening Tailored for HEr (BREATHE)—A study protocol on personalised risk-based breast cancer screening programme

The Doctor Will Talk to You Now: A Discussion on Personalised Breast Cancer Risk in the Clinic

Ability to Predict Breast Cancer in Asian Women Using a Polygenic Susceptibility Model

Presentation of breast cancer, help seeking behaviour and experience of patients in their cancer journey in Singapore: a qualitative study

Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India

The Breast Cancer Genetic Testing Experience: Probing the Potential Utility of an Online Decision Aid in Risk Perception and Decision Making

Risk estimation, anxiety, and breast cancer worry in women at risk for breast cancer: A single‐arm trial of personalized risk communication

Towards Personalized Breast Cancer Risk Management: A Thai Cohort Study on Polygenic Risk Scores

How do women at increased risk of breast cancer make sense of their risk? An interpretative phenomenological analysis

Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study

Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial

Perceived Importance of Breast Cancer Risk Factors: A Survey on 386 Physicians in China

Women's decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals

Women’s health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations

Patient-reported outcome measures among breast cancer survivors: A cross-sectional comparison between Malaysia and high-income countries

Identifying barriers to early presentation in patients with locally advanced breast cancer (LABC) in Northern Singapore: Qualitative study

Psychological impact of providing women with personalised 10-year breast cancer risk estimates

Digital cancer genetic risk assessment in a gynecologic oncology clinic.

Polygenic risk scores for prediction of breast cancer risk in Asian populations

Information needs of women with BRCA mutations regarding cancer risk management and decision-making